Tags

Type your tag names separated by a space and hit enter

[Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis].
Clin Ter. 1993 Dec; 143(6):519-29.CT

Abstract

Open, non comparative study to evaluate the efficacy and safety of piroxicam Fast Dissolving Dosage Form (FDDF) for sublingual administration in treatment of reacutized osteoarthritis. Fifty-four patients with flare-ups of osteoarthritis involving various joints were enrolled in the study. They were treated with 20 mg/die piroxicam sublingual tablets for a total of 4 weeks. Drug efficacy was evaluated on the basis of the variation of spontaneous pain, pain on passive motion, functional limitation and capacity of performing a specific activity. Intensity of spontaneous pain on the first day showed a statistically significant improvement (p < 0.0001) only 15 minutes after the drug administration. This improvement in pain intensity increased until day 3. All other efficacy parameters showed a statistically significant improvement (p < 0.0001) 7 days after the beginning of treatment. Local and systemic tolerability was good. No patient showed local side effects; only 6 patients experienced systemic side effects. In conclusion, piroxicam sublingual tablets for treatment of osteoarthritis flare-ups showed analgesic efficacy already 15 minutes after drug administration, and good anti-inflammatory efficacy with good local and systemic tolerability.

Authors+Show Affiliations

Divisione di Reumatologia, Ospedale S. Camillo di Roma.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
English Abstract
Journal Article

Language

ita

PubMed ID

8306576

Citation

Minisola, G, et al. "[Clinical Experience With the Use of Piroxicam in Fast-dissolving Sublingual Capsules in Acute Recurrent Osteoarthritis]." La Clinica Terapeutica, vol. 143, no. 6, 1993, pp. 519-29.
Minisola G, Bancheri C, Bogliolo A, et al. [Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis]. Clin Ter. 1993;143(6):519-29.
Minisola, G., Bancheri, C., Bogliolo, A., Brundisini, B., Gospodinoff, L., Lucentini, L., Porzio, F., & Perpignano, G. (1993). [Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis]. La Clinica Terapeutica, 143(6), 519-29.
Minisola G, et al. [Clinical Experience With the Use of Piroxicam in Fast-dissolving Sublingual Capsules in Acute Recurrent Osteoarthritis]. Clin Ter. 1993;143(6):519-29. PubMed PMID: 8306576.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Clinical experience with the use of piroxicam in fast-dissolving sublingual capsules in acute recurrent osteoarthritis]. AU - Minisola,G, AU - Bancheri,C, AU - Bogliolo,A, AU - Brundisini,B, AU - Gospodinoff,L, AU - Lucentini,L, AU - Porzio,F, AU - Perpignano,G, PY - 1993/12/1/pubmed PY - 1993/12/1/medline PY - 1993/12/1/entrez SP - 519 EP - 29 JF - La Clinica terapeutica JO - Clin Ter VL - 143 IS - 6 N2 - Open, non comparative study to evaluate the efficacy and safety of piroxicam Fast Dissolving Dosage Form (FDDF) for sublingual administration in treatment of reacutized osteoarthritis. Fifty-four patients with flare-ups of osteoarthritis involving various joints were enrolled in the study. They were treated with 20 mg/die piroxicam sublingual tablets for a total of 4 weeks. Drug efficacy was evaluated on the basis of the variation of spontaneous pain, pain on passive motion, functional limitation and capacity of performing a specific activity. Intensity of spontaneous pain on the first day showed a statistically significant improvement (p < 0.0001) only 15 minutes after the drug administration. This improvement in pain intensity increased until day 3. All other efficacy parameters showed a statistically significant improvement (p < 0.0001) 7 days after the beginning of treatment. Local and systemic tolerability was good. No patient showed local side effects; only 6 patients experienced systemic side effects. In conclusion, piroxicam sublingual tablets for treatment of osteoarthritis flare-ups showed analgesic efficacy already 15 minutes after drug administration, and good anti-inflammatory efficacy with good local and systemic tolerability. SN - 0009-9074 UR - https://www.unboundmedicine.com/medline/citation/8306576/[Clinical_experience_with_the_use_of_piroxicam_in_fast_dissolving_sublingual_capsules_in_acute_recurrent_osteoarthritis]_ L2 - https://medlineplus.gov/osteoarthritis.html DB - PRIME DP - Unbound Medicine ER -